Joy Yan
Chief Tech/Sci/R&D Officer presso KEYMED BIOSCIENCES INC.
Patrimonio netto: - $ in data 29/02/2024
Profilo
Currently, Joy Yan occupies the position of Chief Medical Officer for Keymed Biosciences, Inc. Dr. Yan is also on the board of Moleculin Biotech, Inc.
In her past career Dr. Yan was Director-Clinical Development at Bayer AG, Chief Medical Officer for Ambrx, Inc. and Chief Medical Officer for Ambrx Biopharma Cayman, Inc.
Joy Yan received a doctorate from The Johns Hopkins University and a doctorate from China Medical University.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
MOLECULIN BIOTECH, INC.
-.--% | 26/12/2023 | 0 ( -.--% ) | - $ | 29/02/2024 |
Posizioni attive di Joy Yan
Società | Posizione | Inizio |
---|---|---|
MOLECULIN BIOTECH, INC. | Director/Board Member | 01/03/2022 |
KEYMED BIOSCIENCES INC. | Chief Tech/Sci/R&D Officer | 01/01/2022 |
Precedenti posizioni note di Joy Yan
Società | Posizione | Fine |
---|---|---|
CHECKMATE PHARMACEUTICALS, INC. | Director/Board Member | 31/05/2022 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Chief Tech/Sci/R&D Officer | - |
BAYER AG | Corporate Officer/Principal | - |
AMBRX INC | Chief Tech/Sci/R&D Officer | - |
Formazione di Joy Yan
The Johns Hopkins University | Doctorate Degree |
China Medical University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
BAYER AG | Health Technology |
KEYMED BIOSCIENCES INC. | Health Technology |
Aziende private | 4 |
---|---|
Ambrx, Inc.
Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
Moleculin Biotech, Inc. | |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Health Technology |